Oncology APIs Portfolio Sourcing Solutions
Pharmabridge offers a focused portfolio of high-value Oncology Active Pharmaceutical Ingredients (APIs) for pharmaceutical manufacturers, formulation companies, contract manufacturers, and development partners. Our portfolio includes cytotoxic chemotherapeutics, targeted kinase inhibitors, and precision oncology APIs.
Featured Products in Oncology APIs Portfolio
Paclitaxel IP / USP / EP
Paclitaxel is a complex diterpenoid taxane antineoplastic API (C47H51NO14, CAS 33069-62-4) that stabilizes microtubules to interfere with cancer cell division. Indicated in ovarian cancer, breast cancer, non-small-cell lung cancer (NSCLC), and Kaposi sarcoma.
Docetaxel Trihydrate & Anhydrous IP / USP / EP
Docetaxel is a semi-synthetic taxane microtubule inhibitor. Available in Trihydrate (CAS 148408-66-6, C43H53NO14·3H2O, MW 861.93 g/mol) and Anhydrous (CAS 114977-28-5, C43H53NO14, MW 807.88 g/mol) forms for breast, NSCLC, prostate, gastric, and head/neck cancers.
Cabazitaxel – Solvated & Amorphous
Cabazitaxel is a semi-synthetic taxane antineoplastic API (CAS 183133-96-2) offered in Solvated (1:1 acetone solvatomorph) and Amorphous forms. Indicated in combination with prednisone for metastatic castration-resistant prostate cancer (mCRPC).
Carfilzomib Proteasome Inhibitor
Carfilzomib is a next-generation epoxyketone 20S proteasome inhibitor (C40H57N5O7, MW 719.91 g/mol) for relapsed or refractory multiple myeloma, inducing malignant plasma cell apoptosis.
Carmustine (BCNU) Nitrosourea API
Carmustine (BCNU) is a nitrosourea alkylating agent that crosses the blood-brain barrier. Indicated in glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, multiple myeloma, and Hodgkin/Non-Hodgkin lymphoma.
Etoposide Topoisomerase II Inhibitor
Etoposide is a podophyllotoxin-derived Topoisomerase II inhibitor (C29H32O13, CAS 33419-42-0). Widely used in combination chemotherapy for Small Cell Lung Cancer (SCLC) and refractory testicular cancer.
Lomustine (CCNU) Oral Nitrosourea API
Lomustine (CCNU) is an orally active nitrosourea alkylating agent (C9H16ClN3O2) capable of crossing the blood-brain barrier for primary brain tumors, metastatic brain lesions, and Hodgkin lymphoma.
Topotecan / Topotecan HCl Topoisomerase I Inhibitor
Topotecan is a semi-synthetic camptothecin derivative Topoisomerase I inhibitor used in metastatic ovarian cancer, Small Cell Lung Cancer (SCLC), and advanced cervical cancer.
Ponatinib T315I BCR::ABL Kinase Inhibitor
Ponatinib is a targeted tyrosine kinase inhibitor (C29H27F4N6O) inhibiting ABL/BCR::ABL, including the T315I mutant form in Philadelphia chromosome-positive ALL and Chronic Myeloid Leukemia (CML).
Pazopanib Multi-Target TKI API
Pazopanib is an oral multi-target tyrosine kinase inhibitor targeting VEGFR-1/2/3, PDGFR-α/β, and FGFR-1/3 for Advanced Renal Cell Carcinoma (RCC) and Soft Tissue Sarcoma (STS).
Olaparib PARP Inhibitor Precision Oncology API
Olaparib is a PARP1/2/3 inhibitor (C24H23FN4O3) for biomarker-selected BRCA-mutated and HRR-gene-mutated ovarian, breast, pancreatic, and prostate cancers.
Irinotecan / Irinotecan HCl Topoisomerase I Inhibitor
Irinotecan Hydrochloride is a camptothecin-derived prodrug converted to active metabolite SN-38. Core component in first-line and refractory metastatic colorectal cancer chemotherapy (FOLFIRI).
Why Source Oncology APIs Portfolio Through Pharmabridge?
We verify your exact pharmacopeial grade, assay requirements, mesh size, and impurity limits.
Full audit documentation, COA, MOA, Stability Data, and DMF compliance packages.
Cold chain and temperature-monitored shipping options for sensitive active compounds.